Overview

TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

Status:
Active, not recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

PURPOSE: This trial is studying if and how well lapatinib adds to the effectiveness of radiation therapy plus cisplatin in patients who have head and neck cancer that is not related to the HPV virus.

Phase:

Phase 2

Details

Lead Sponsor:

Radiation Therapy Oncology Group

Collaborators:

GlaxoSmithKline
Novartis
NRG Oncology

Treatments:

Cisplatin
Lapatinib